BIOMAT Database Logo BIOMAT Database Logo

Aerosolized amphotericin B lipid complex and invasive pulmonary aspergillosis: a case report. 2015

Diana Canetti, and Angelo Cazzadori, and Irene Adami, and Francesca Lifrieri, and Stefania Cristino, and Ercole Concia
Infectious Diseases Unit, Azienda Ospedaliero-Universitaria Integrata di Verona, Italy; Nephrology and Dialysis Unit, Ospedale Pierantoni-Morgagni, Forli, Italy.

Invasive pulmonary aspergillosis (IPA) is an emerging life-threatening infection in immuno-compromised patients. The incidence of IPA following kidney transplantation is low (between 0.7 and 4%), yet mortality remains unacceptably high (75-80%). A first line therapy with voriconazole or lipid formulations of amphotericin B is often limited by co-morbidities, adverse effects and drug interactions. The case within this publication is the first described report of IPA in a renal transplant recipient responding to aerosolized amphotericin B lipid complex.

UI MeSH Term Description Entries
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000336 Aerosols Colloids with a gaseous dispersing phase and either liquid (fog) or solid (smoke) dispersed phase; used in fumigation or in inhalation therapy; may contain propellant agents. Aerosol
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal
D016867 Immunocompromised Host A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation. Immunosuppressed Host,Immunocompromised Patient,Host, Immunocompromised,Host, Immunosuppressed,Hosts, Immunocompromised,Hosts, Immunosuppressed,Immunocompromised Hosts,Immunocompromised Patients,Immunosuppressed Hosts,Patient, Immunocompromised,Patients, Immunocompromised
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D055744 Invasive Pulmonary Aspergillosis Lung infections with the invasive forms of ASPERGILLUS, usually after surgery, transplantation, prolonged NEUTROPENIA or treatment with high-doses of CORTICOSTEROIDS. Invasive pulmonary aspergillosis can progress to CHRONIC NECROTIZING PULMONARY ASPERGILLOSIS or hematogenous spread to other organs. Allergic Bronchopulmonary Mycosis,Chronic Necrotizing Pulmonary Aspergillosis,Pulmonary Aspergillosis - Invasive,Allergic Bronchopulmonary Mycoses,Aspergillosis, Invasive Pulmonary,Bronchopulmonary Mycoses, Allergic,Bronchopulmonary Mycosis, Allergic,Mycoses, Allergic Bronchopulmonary,Mycosis, Allergic Bronchopulmonary,Pulmonary Aspergilloses, Invasive,Pulmonary Aspergillosis Invasive,Pulmonary Aspergillosis, Invasive

Related Publications

Diana Canetti, and Angelo Cazzadori, and Irene Adami, and Francesca Lifrieri, and Stefania Cristino, and Ercole Concia
Aerosolized amphotericin B as prophylaxis for invasive pulmonary aspergillosis: a meta-analysis.
January 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,
Diana Canetti, and Angelo Cazzadori, and Irene Adami, and Francesca Lifrieri, and Stefania Cristino, and Ercole Concia
Aerosolized amphotericin B in prophylaxis of pulmonary aspergillosis.
October 1996, The Annals of pharmacotherapy,
Diana Canetti, and Angelo Cazzadori, and Irene Adami, and Francesca Lifrieri, and Stefania Cristino, and Ercole Concia
Aerosolized liposomal Amphotericin B: a potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients.
June 2014, Pediatric pulmonology,
Diana Canetti, and Angelo Cazzadori, and Irene Adami, and Francesca Lifrieri, and Stefania Cristino, and Ercole Concia
Inhaled amphotericin B lipid complex for prophylaxis against COVID-19-associated invasive pulmonary aspergillosis.
March 2022, Intensive care medicine,
Diana Canetti, and Angelo Cazzadori, and Irene Adami, and Francesca Lifrieri, and Stefania Cristino, and Ercole Concia
Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.
August 2010, Antimicrobial agents and chemotherapy,
Diana Canetti, and Angelo Cazzadori, and Irene Adami, and Francesca Lifrieri, and Stefania Cristino, and Ercole Concia
Aerosolized Lipid Amphotericin B for Complementary Therapy and/or Secondary Prophylaxis in Patients with Invasive Pulmonary Aspergillosis: A Single-Center Experience.
April 2019, Mycopathologia,
Diana Canetti, and Angelo Cazzadori, and Irene Adami, and Francesca Lifrieri, and Stefania Cristino, and Ercole Concia
Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats.
July 2001, The Journal of antimicrobial chemotherapy,
Diana Canetti, and Angelo Cazzadori, and Irene Adami, and Francesca Lifrieri, and Stefania Cristino, and Ercole Concia
Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
March 2008, Cancer,
Diana Canetti, and Angelo Cazzadori, and Irene Adami, and Francesca Lifrieri, and Stefania Cristino, and Ercole Concia
Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients.
May 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Diana Canetti, and Angelo Cazzadori, and Irene Adami, and Francesca Lifrieri, and Stefania Cristino, and Ercole Concia
Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis.
September 2004, Bone marrow transplantation,
Copied contents to your clipboard!